MUC1 Expression in Colorectal Cancer is Associated with Malignant Clinicopathological Factors

This study aimed to evaluate the frequency, distribution, and corresponding histology of MUC1 expression in colorectal cancer and examine its association with clinicopathological factors. MUC1 expression was con rmed in 86 of 169 surgically resected colorectal cancers (51%), although the ratio of MUC1-positive cells was less than 5% in 33 cases (20%), 5-50% in 46 cases (27%), and greater than 50% in only 7 cases (4%). None or less than 5% of MUC1 expression cases were classi ed as L-group cancers (116 cases, 69%), while cancers showing higher than 5% expression were classi ed into the H-group (53 cases, 31%). Analysis of the intratumoral distribution of positive cells in the H-group cases showed MUC1 expression distributed predominantly in the upper layers in 3 cases (6%), in the lower layers in 18 cases (34%), and in all layers in 32 cases (60%). MUC1 expression was observed in various histomorphological cancer forms, but the most frequent expression was noted in the monolayer cuboidal (pancreatobiliary-type) neoplastic glands. Considering the relationship between MUC1 expression and clinicopathological factors, H-group cases demonstrated signi cantly larger lesions showing a greater number of ulcerated-type cancers, deeper invasion, poorer differentiation, higher frequency of budding, and higher rate of lymph node metastasis than L-group cancers. Furthermore, there was a difference of 10% between the H-group and L-group with regard to the frequency of relapse/tumor mortality three years after surgery. In colorectal cancer, MUC1 expression increases with progression of the tumor indicating that it is one of the useful indicators of malignancy and may facilitate appropriate treatment regimens ; however, as its expression is heterogeneous and localized, it will be necessary to con rm the state of MUC1 expression by case.

[1]  Takeshi Suzuki,et al.  Application of Autofluorescence Endoscopy for Colorectal Cancer Screening: Rationale and an Update , 2011, Gastroenterology research and practice.

[2]  Mei Xu,et al.  CDX2 as a marker for intestinal differentiation: Its utility and limitations. , 2011, World journal of gastrointestinal surgery.

[3]  E. Oki,et al.  A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: A Japanese experience , 2011, Surgery Today.

[4]  H. Nagawa,et al.  [FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer]. , 2011, Gan to kagaku ryoho. Cancer & chemotherapy.

[5]  X. Puig,et al.  Clinicopathological and molecular characterization of colorectal micropapillary carcinoma , 2011, Modern Pathology.

[6]  Xiong-zeng Zhu,et al.  [Expression of mucin glycoproteins and cytokeratins in intrahepatic cholangiocarcinoma]. , 2008, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[7]  T. Yeh,et al.  Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges? , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[8]  M. Oka,et al.  Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. , 2008, Oncology reports.

[9]  J. Gama-Rodrigues,et al.  Mucinous colorectal adenocarcinoma: influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis , 2008, International Journal of Colorectal Disease.

[10]  K. Chayama,et al.  Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer. , 2007, World journal of gastroenterology.

[11]  J. Scholefield,et al.  The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer , 2007, World journal of surgical oncology.

[12]  I. Kazantseva,et al.  [Expression of type 1 and type 2 mucins in colonic epithelial tumors]. , 2007, Arkhiv patologii.

[13]  Jinn Shiun Chen,et al.  Inverse Effects of Mucin on Survival of Matched Hereditary Nonpolyposis Colorectal Cancer and Sporadic Colorectal Cancer Patients , 2006, Clinical Cancer Research.

[14]  A. Hölscher,et al.  MUC1 and Nuclear β-Catenin Are Coexpressed at the Invasion Front of Colorectal Carcinomas and Are Both Correlated with Tumor Prognosis , 2004, Clinical Cancer Research.

[15]  Xiao-qun Zhu,et al.  [Expression of mucin MUC1 and MUC2 in colorectal carcinoma and their clinical significance]. , 2002, Ai zheng = Aizheng = Chinese journal of cancer.

[16]  A. Hölscher,et al.  Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl‐Lewisa and sialyl‐Lewisx antigens in colorectal adenocarcinoma , 2002, Histopathology.

[17]  S. Chae,et al.  Coexpression of MUC1 with p53 or MUC2 correlates with lymph node metastasis in colorectal carcinomas. , 2002, Journal of Korean medical science.

[18]  N. Kohno,et al.  Immunoreactive MUC1 Expression at the Deepest Invasive Portion Correlates with Prognosis of Colorectal Cancer , 1998, Oncology.

[19]  D. Ota,et al.  MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. , 1994, Gastroenterology.